Influence of age on the clinical outcomes of coronary revascularisation for the treatment of patients with multivessel de novo coronary artery lesions: sirolimus-eluting stent vs. coronary artery bypass surgery and bare metal stent, insight from the multicentre randomised Arterial Revascularisation Therapy Study Part I (ARTS-I) and Part II (ARTS-II)

被引:7
|
作者
Legrand, Victor M. [2 ]
Garg, Scot [1 ]
Serruys, Patrick W. [1 ]
Virtanen, Kari S. [3 ]
Szurawitzki, Guenter [4 ]
Voudris, Vassilis [5 ]
Fontanelli, Alessandro [6 ]
Endersen, Knut [7 ]
Kranjec, Igor [8 ]
Rademaker, Tessa [9 ]
Stefanidis, Christodoulos I. [10 ]
Wittebols, Kristel [11 ]
机构
[1] Erasmus MC, Thoraxctr, NL-3015 GD Rotterdam, Netherlands
[2] CHU Sart Tilman, B-4000 Liege, Belgium
[3] Univ Helsinki, Cent Hosp, Helsinki, Finland
[4] Elisabeth Hosp, Essen, Germany
[5] Onassis Cardiac Surg Ctr, Athens, Greece
[6] San Bortolo Hosp, Vicenza, Italy
[7] Riskhosp, Oslo, Norway
[8] Clin Ctr Ljubljana, Ljubljana, Slovenia
[9] Cardialysis BV, Rotterdam, Netherlands
[10] Hippokrateion Hosp, Athens, Greece
[11] Johnson & Johnson Co, Cordis, Waterloo, Belgium
关键词
Ageing; coronary artery disease; revascularisation; bare metal stents; sirolimus-eluting stents; surgery; GREATER-THAN-OR-EQUAL-TO-80; YEARS; DIABETES-MELLITUS; ELDERLY-PATIENTS; CARDIAC-SURGERY; FOLLOW-UP; INTERVENTION; DISEASE; MORTALITY; EUROSCORE; STRATEGY;
D O I
10.4244/EIJV6I7A144
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: We sought to evaluate the prognostic impact of age on the procedural results and subsequent clinical outcomes in patients with multivessel disease (MVD) treated either by coronary artery bypass surgery (CABG) or by percutaneous coronary intervention (PCI) with or without drug eluting stents, based on data of the Arterial Revascularisation Therapies Study (ARTS) part land part II. The potential influence of age in determining the most appropriate revascularisation strategy for patients with MVD is largely unknown. Methods and results: Three year clinical outcome of ARTS I patients randomised to PCI with bare metal stent (BMS) (n= 600) or CABG (n= 605), and matched patients treated by PCI with sirolimus-eluting stents (SES) in ARTS II (n= 607) were reviewed according to four age quartiles. Endpoints were measured in terms of major adverse cardiac and cerebrovascular events MACCE) during hospital stay and up to three years. The frequency of female, diabetes, hypertension, peripheral vascular disease, pulmonary disease, as well as lesion complexity increased with age. At three years, MACCE free survival was comparable between patients treated by CABG or SES PCI, regardless of age quartile. The incidence of MACCE was higher among ARTS I BMS treated patients in all but the second age quartile. This was primarily related to a higher need for repeat revascularisation among BMS treated patients. However, age, which emerged as a strong independent predictor of MACCE following CABG (p<0.005), was not predictive of adverse events following PCI. Conversely, diabetes was the strongest independent predictor of MACCE among PCI treated patients (p<0.02), but didn't affect three-year outcomes following CABG. Conclusions: Age seems to influence the CABG outcome in-hospital but not PCI. PCI-SES could offer lower immediate risk in patients with MVD and comparable long-term outcome as CABG especially in older patients. The worst outcome of PCI-BMS group is primarily related to the need for repeat revascularisation. Diabetes is the most important predictor of MACCE following PCI.
引用
收藏
页码:838 / 845
页数:8
相关论文
共 6 条
  • [1] 5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions
    Serruys, Patrick W.
    Onuma, Yoshinobu
    Garg, Scot
    Vranckx, Pascal
    De Bruyne, Bernard
    Morice, Marie-Claude
    Colombo, Antonio
    Macaya, Carlos
    Richardt, Gert
    Fajadet, Jean
    Hamm, Christian
    Schuijer, Monique
    Rademaker, Tessa
    Wittebols, Kristel
    Stoll, Hans Peter
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (11) : 1093 - 1101
  • [2] Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II)
    Routledge, Helen C.
    Lefevre, Thierry
    Colombo, Antonio
    Oldroyd, Keith G.
    Hamm, Christian W.
    Guagliumi, Giulio
    von Scheidt, Wolfgang
    Guetta, Victor
    Ruzyllo, Witold
    Wittebols, Kristel
    Goedhart, Dick M.
    Serruys, Patrick W.
    EUROINTERVENTION, 2009, 5 (02) : 190 - 196
  • [3] Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease
    van Domburg, Ron T.
    Daemen, Joost
    Morice, Marie-Claude
    de Bruyne, Bernard
    Colombo, Antonio
    Macaya, Carlos
    Richardt, Gert
    Fajadet, Jean
    Hamm, Christian
    van Es, Gerrit-Anne
    Wittebols, Kristel
    Macours, Nathalie
    Stoll, Hans Peter
    Serruys, Patrick W.
    EUROINTERVENTION, 2010, 5 (08) : 962 - 967
  • [4] Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II)
    Kukreja, N.
    Serruys, P. W.
    De Bruyne, B.
    Colombo, A.
    Macaya, C.
    Richardt, G.
    Fajadet, J.
    Hamm, C.
    Goedhart, D.
    Macours, N.
    Stoll, H. P.
    HEART, 2009, 95 (13) : 1061 - 1066
  • [5] 5-Year Follow-Up of Coronary Revascularization in Diabetic Patients With Multivessel Coronary Artery Disease Insights From ARTS (Arterial Revascularization Therapy Study)-II and ARTS-I Trials
    Onuma, Yoshinobu
    Wykrzykowska, Joanna J.
    Garg, Scot
    Vranckx, Pascal
    Serruys, Patrick W.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (03) : 317 - 323
  • [6] Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial
    Xu, Bo
    Dou, Kefei
    Yang, Yuejin
    Lv, Shuzheng
    Wang, Lefeng
    Wang, Haichang
    Li, Zhanquan
    Wang, Lei
    Chen, Yundai
    Huo, Yong
    Li, Wei
    Kirtane, Ajay J.
    Gao, Runlin
    EUROINTERVENTION, 2012, 8 (07) : 796 - 802